Similar articles

• Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis.

  Weinstein GD, Cox JW, Suringa DW, Millard MM, Kalser M, Frost P. Weinstein GD, et al. Arch Dermatol. 1970 Dec;102(6):613-8. Arch Dermatol. 1970. PMID: 5501902 No abstract available.
• Methotrexate induced hepatitis in childhood leukemia.

  Taft LI. Taft LI. Isr J Med Sci. 1965 Jul;1(4):823-7. Isr J Med Sci. 1965. PMID: 5856123 No abstract available.
• The canals of hering might represent a target of methotrexate hepatic toxicity.

  Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND. Hytiroglou P, et al. Am J Clin Pathol. 2004 Mar;121(3):324-9. doi: 10.1309/5HR9-0TNC-4Q4J-RXWX. Am J Clin Pathol. 2004. PMID: 15023035
• Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.

  Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, Smith C; International Psoriasis Council. Barker J, et al. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):758-64. doi: 10.1111/j.1468-3083.2010.03932.x. Epub 2010 Dec 29. J Eur Acad Dermatol Venereol. 2011. PMID: 21198946 Review.
• [Liver damage in methotrexate-treated patients. When liver biopsy is necessary in the follow-up?].

  Nieminen U, Höök-Nikanne J, Kärkkäinen P, Niemelä S. Nieminen U, et al. Duodecim. 2005;121(24):2680-8. Duodecim. 2005. PMID: 16454249 Review. Finnish. No abstract available.